474 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Deeptag-Gprc5D Targeted Car T-Cells Plasma Cell Myeloma	He Huang	P1	CC (43)
Defactinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Degarelix Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Descartes-15 Plasma Cell Myeloma	Cartesian Therapeutics	P1	CC (43)
Dual-Targeting Bcma-Gprc5D Car-T Cell Infusion Plasma Cell Myeloma	Beijing GoBroad Hospital	P1	CC (43)
Elranatamab-Bcmm Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Emapalumab Plasma Cell Myeloma	NYU Langone Health	P2	CC (43)
ezm0414 Plasma Cell Myeloma	Epizyme, Inc.	P1	CC (43)
Fam-Trastuzumab Deruxtecan-Nxki Plasma Cell Myeloma	American Society of Clinical Oncology	P2	CC (43)
ft836 car t cells Plasma Cell Myeloma	Medical College of Wisconsin	P1	CC (43)
Human Hyaluronidase Isozyme-5 (Hyal5, Sperm Adhesion Molecule 1, Spam1, Hyaluronidase Ph-20, Ec:3.2.1.35) Fragment (3-433, 1-431 In The Current Sequence) Engineered Variant With The Structural Domain Replaced By The Corresponding Region Of Human Hyaluronidase Isozyme-1 (Hyal1)(<Sup>306</Sup>Tlsimrsmkscllddnymeti<Sup>326</Sup>><Sup>304</Sup>Swentrtkescqaikeymdtt<Sup>324</Sup>), Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Dg44, Glycoform Alfa Plasma Cell Myeloma	Barbara Ann Karmanos Cancer Institute	P2	CC (43)
Ifa Plasma Cell Myeloma	Roswell Park Cancer Institute	P1	CC (43)
Igpro20 Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Indium In 111-Dota-Daratumumab Plasma Cell Myeloma	City of Hope Medical Center	P1	CC (43)
Interleukin 18 (Recombinant Human Mutein Clone St-067) Plasma Cell Myeloma	University of Washington	P1	CC (43)
Ipatasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Kappa Cd28 T Cells Plasma Cell Myeloma	Baylor College of Medicine	P1	CC (43)
Kln-1010 Plasma Cell Myeloma	Kelonia Therapeutics, Inc.	P1	CC (43)
Larotrectinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Leuporelin Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Liposomal Curcumin Plasma Cell Myeloma	University Health Network, Toronto	P1	CC (43)
Mdc-Car-Bcma001 Plasma Cell Myeloma	Technische Universität Dresden	P1	CC (43)
Mecapegfilgrastim Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (43)
Mit-001 Plasma Cell Myeloma	MitoImmune Therapeutics	P2	CC (43)
mk-4002 Plasma Cell Myeloma	Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	P1	CC (43)
Mm-Specific Universal Car T Cells Plasma Cell Myeloma	Shenzhen Geno-Immune Medical Institute	P1	CC (43)
Opn-6602 Plasma Cell Myeloma	Opna Bio LLC	P1	CC (43)
Osimertinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Oxodotreotide Plasma Cell Myeloma	Jules Bordet Institute	P1	CC (43)
pd-1ab21-bcma car-t cell immunotherapy Plasma Cell Myeloma	Daihong Liu	P2	CC (43)
Plinabulin Plasma Cell Myeloma	Memorial Sloan Kettering Cancer Center	P2	CC (43)
Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta Plasma Cell Myeloma	Mayo Clinic	P1	CC (43)
Rimiducid Plasma Cell Myeloma	Poseida Therapeutics, Inc.	P1/2	CC (43)
sar446523 Plasma Cell Myeloma	Sanofi	P1	CC (43)
Selvigaltin Plasma Cell Myeloma	Roswell Park Cancer Institute	P1	CC (43)
Survaxm Plasma Cell Myeloma	Roswell Park Cancer Institute	P1	CC (43)
SX682 Plasma Cell Myeloma	Roswell Park Cancer Institute	P1	CC (43)
Talazoparib Plasma Cell Myeloma	American Society of Clinical Oncology	P2	CC (43)
Tcr Transduced T-Cells Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Tucatinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (43)
Ulixertinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Adavosertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (42)
Bosutinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (42)
Taselisib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (42)
3x10 cart-38 cells Plasma Cell Myeloma	University of Pennsylvania	P1	CC (41)
Alnuctamab Plasma Cell Myeloma	Celgene	P3	CC (41)
br101 Plasma Cell Myeloma	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	P1	CC (41)
Car-Gprc5D Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P1	CC (41)
Car-T（Rd140 ） Plasma Cell Myeloma	Peking University People's Hospital	P1	CC (41)
cb-011 Plasma Cell Myeloma	Caribou Biosciences, Inc.	P1	CC (41)

Showing 251 to 300 of 474 assets

PreviousPage 6 of 10Next